Jefferies Group’s Akcea Therapeutics Inc AKCA Stock Holding History

Jefferies Group’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-10,840	Closed	-$254K	–	3202
2019 Q2	$254K	Buy	+10,840	New	+$268K	﹤0.01%	2008

Other funds holding AKCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Jefferies Group's AKCA Position: Q3 2019 in Review

Jefferies Group sold out of Akcea Therapeutics Inc (AKCA) in Q3 2019, closing a stake of 10,840 shares — an estimated $254K sold.

Jefferies Group first reported a position in AKCA in Q2 2019 and held it in 1 quarter. The position peaked at $254K in Q2 2019. 62 funds tracked by Wall St. Rank hold AKCA as of Q3 2019.

Jefferies Group reported no remaining Akcea Therapeutics Inc position as of Q3 2019 after selling out during the quarter.
Jefferies Group sold 10,840 Akcea Therapeutics Inc shares in Q3 2019, an estimated $254K.
Jefferies Group first reported a position in Akcea Therapeutics Inc in Q2 2019 and held it in 1 quarter.
Jefferies Group's Akcea Therapeutics Inc position peaked at $254K in Q2 2019.
62 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q3 2019.

Based on Jefferies Group's 13F filing for Q3 2019, filed 13 Nov 2019.